CytoKi Pharma is a pre-clinical biotechnology company with focus on serious diseases caused by epithelial injury having an unmet medical need. Cytoki’s lead program is an engineered long-acting IL-22 protein licensed from a major pharmaceutical company.
A correctly functioning immune system is essential for keeping us healthy in the multitude of challenges our organism encounters. Numerous medicines are based on principles that activate or deactivate key proteins in the immune system in a disease context. IL-22 is a key cytokine (a class of proteins released from immune cells) in securing the survival and repair after an injury. It is the immune system’s “Survive and Recover” signal to the tissue. Our lead program is harnessing the power of IL-22, in treatment of organ injuries, through a modified IL-22 protein engineered to have optimal pharmaceutical properties.
CytoKi was founded in 2019 and received the first seed financing from Lundbeckfonden Emerge in July 2019. The company has strong focus on progressing the lead program to clinical testing with start of Phase 1 in late 2022. At the same time, CytoKi is maturing a small, diversified portfolio of projects for diseases involving epithelial injury based on IL-22 biology and a highly proven technology for protein engineering. The company is run in a capital efficient way with a small, experienced team coordinating activities performed at selected service providers.
A correctly functioning immune system is essential for keeping us healthy in the multitude of challenges our organism encounters. Numerous medicines are based on principles that activate or deactivate key proteins in the immune system in a disease context. IL-22 is a key cytokine (a class of proteins released from immune cells) in securing the survival and repair after an injury. It is the immune system’s “Survive and Recover” signal to the tissue. Our lead program is harnessing the power of IL-22, in treatment of organ injuries, through a modified IL-22 protein engineered to have optimal pharmaceutical properties.
CytoKi was founded in 2019 and received the first seed financing from Lundbeckfonden Emerge in July 2019. The company has strong focus on progressing the lead program to clinical testing with start of Phase 1 in late 2022. At the same time, CytoKi is maturing a small, diversified portfolio of projects for diseases involving epithelial injury based on IL-22 biology and a highly proven technology for protein engineering. The company is run in a capital efficient way with a small, experienced team coordinating activities performed at selected service providers.
Location: Denmark, Gentofte Municipality
Employees: 1-10
Total raised: $45M
Founded date: 2019
Investors 2
| Date | Name | Website |
| - | ND CAPITAL | nd.capital |
| - | Ysios Capi... | ysioscapit... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.05.2021 | Series A | $45M | ND CAPITAL |
Mentions in press and media 4
| Date | Title | Description |
| 15.12.2023 | What are Hovedstaden’s Most Influential Biotechnology Startups in 2023? | The Biotechnology industry is actively evolving at a rapid pace, and startups from across the globe are continually developing innovative solutions to combat various health and environmental challenges. The flourishing biotechnology scene i... |
| 09.09.2023 | Bio-Innovation Blooms: 15 Cutting-Edge Biotechnology Startups from Denmark | Denmark, known for its picturesque landscapes and rich culture, is also a fertile ground for biotechnology startups. In this article, we’ll take you on a journey to discover 15 remarkable Danish biotech startups that are pushing the boundar... |
| 05.05.2021 | Cytoki Pharma secures $45M Series A round lead by Lundbeckfonden Emerge together with Ysios, Seventure Partners and +ND Capital | 05/05/2021 Press release CYTOKI PHARMA RAISES $45 MILLION SERIES A FINANCING. Proceeds to support the development of its lead program (lipidated IL-22) through clinical proof of concept in Inflammatory Bowel Disease and explore expansion... |
| 05.05.2021 | Cytoki Pharma cierra una ronda de €38M liderada por Lundbeckfonden Emerge junto con Ysios Capital, Seventure Partners y +ND Capital | 05/05/2021 Nota de prensa YSIOS CAPITAL INVIERTE EN CYTOKI PHARMA. − La compañía biotecnológica Cytoki Pharma (Copenhague, Dinamarca) desarrolla nuevas proteínas basadas en interleuquina 22 (IL-22) para el tratamiento de lesiones epiteli... |